Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have received an average rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $34.00.

RCUS has been the topic of a number of research analyst reports. Wells Fargo & Company began coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price target on the stock. Barclays lifted their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. HC Wainwright restated a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th.

Arcus Biosciences Stock Down 2.3 %

RCUS opened at $15.44 on Monday. The company has a fifty day moving average of $16.24 and a two-hundred day moving average of $16.03. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a fifty-two week low of $13.52 and a fifty-two week high of $20.31. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -4.90 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter in the prior year, the firm posted ($0.94) EPS. Arcus Biosciences’s quarterly revenue was up 50.0% compared to the same quarter last year. On average, research analysts expect that Arcus Biosciences will post -3.2 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences in the third quarter valued at approximately $47,000. Innealta Capital LLC purchased a new stake in Arcus Biosciences in the 2nd quarter valued at $66,000. Point72 DIFC Ltd acquired a new stake in shares of Arcus Biosciences in the 2nd quarter worth $83,000. Quest Partners LLC raised its holdings in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the period. Finally, Diversified Trust Co raised its holdings in shares of Arcus Biosciences by 12.1% during the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after acquiring an additional 1,467 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.